Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib

INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessme...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowara, Elzbieta, Huszno, Joanna, Slomian, Grzegorz, Nieckula, Jaroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/
https://www.ncbi.nlm.nih.gov/pubmed/26985180
http://dx.doi.org/10.5114/pdia.2015.48045
_version_ 1782421334582624256
author Nowara, Elzbieta
Huszno, Joanna
Slomian, Grzegorz
Nieckula, Jaroslaw
author_facet Nowara, Elzbieta
Huszno, Joanna
Slomian, Grzegorz
Nieckula, Jaroslaw
author_sort Nowara, Elzbieta
collection PubMed
description INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessment of the incidence of skin cancer. MATERIAL AND METHODS: We carried out a systematic study of patients (pts) treated with vemurafenib. Skin toxicity during vemurafenib therapy was analyzed. Toxicity was determined on the basis of the toxicity scale CTCAE, version 4.0. RESULTS: The most common cutaneous side effects were hyperkeratotic perifollicular rash (69%) and photosensitivity (15%). Skin rash developed more frequently in the first month of treatment. Squamous cell carcinoma occurred in 38% of patients. Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4. Skin cancer developed more often in women than in men (60% vs. 25%), p = 0.249. It was detected only in patients with normal weight compared to overweight patients (55% vs. 0), p = 0.09. The median OS was 26 months and median OS from the time of distant metastases diagnosis was 9.8 months. In patients with a low body mass index, shorter OS was observed, p = 0.09. CONCLUSIONS: The incidence of squamous cell carcinoma was high (38%). This study has many limitations mostly due to a small group of patients. That is why the results should be taken into consideration with caution. The proper symptomatic treatment in cooperation with dermatologists allows to continue the vemurafenib therapy.
format Online
Article
Text
id pubmed-4793055
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-47930552016-03-16 Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib Nowara, Elzbieta Huszno, Joanna Slomian, Grzegorz Nieckula, Jaroslaw Postepy Dermatol Alergol Original Paper INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessment of the incidence of skin cancer. MATERIAL AND METHODS: We carried out a systematic study of patients (pts) treated with vemurafenib. Skin toxicity during vemurafenib therapy was analyzed. Toxicity was determined on the basis of the toxicity scale CTCAE, version 4.0. RESULTS: The most common cutaneous side effects were hyperkeratotic perifollicular rash (69%) and photosensitivity (15%). Skin rash developed more frequently in the first month of treatment. Squamous cell carcinoma occurred in 38% of patients. Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4. Skin cancer developed more often in women than in men (60% vs. 25%), p = 0.249. It was detected only in patients with normal weight compared to overweight patients (55% vs. 0), p = 0.09. The median OS was 26 months and median OS from the time of distant metastases diagnosis was 9.8 months. In patients with a low body mass index, shorter OS was observed, p = 0.09. CONCLUSIONS: The incidence of squamous cell carcinoma was high (38%). This study has many limitations mostly due to a small group of patients. That is why the results should be taken into consideration with caution. The proper symptomatic treatment in cooperation with dermatologists allows to continue the vemurafenib therapy. Termedia Publishing House 2016-02-29 2016-02 /pmc/articles/PMC4793055/ /pubmed/26985180 http://dx.doi.org/10.5114/pdia.2015.48045 Text en Copyright © 2016 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Nowara, Elzbieta
Huszno, Joanna
Slomian, Grzegorz
Nieckula, Jaroslaw
Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title_full Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title_fullStr Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title_full_unstemmed Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title_short Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
title_sort skin toxicity in braf(v600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/
https://www.ncbi.nlm.nih.gov/pubmed/26985180
http://dx.doi.org/10.5114/pdia.2015.48045
work_keys_str_mv AT nowaraelzbieta skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib
AT husznojoanna skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib
AT slomiangrzegorz skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib
AT nieckulajaroslaw skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib